Penumbra Inc (PEN)
229.17
-4.13
(-1.77%)
USD |
NYSE |
Nov 04, 16:00
229.17
0.00 (0.00%)
After-Hours: 20:00
Price Chart
Key Stats
Price and Performance | |
---|---|
Market Cap | 8.795B |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | 20.22% |
Valuation | |
PE Ratio | 266.48 |
PE Ratio (Forward) | Upgrade |
PS Ratio | 7.713 |
Price to Book Value | 7.965 |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | -- |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | 0.00 |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | 62.64% |
Profile
Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are sold to hospitals and are developed for use by specialist physicians. The neurovascular product category contributes to the majority of revenue. Within the neurovascular business, the firm offers products for neurovascular access, ischemic stroke, neurovascular embolization, and neurosurgical tool markets. In the peripheral vascular business, the firm sells devices related to peripheral embolization and peripheral thrombectomy. Penumbra generates the majority of its revenue in the United States. |
URL | https://www.penumbrainc.com |
Investor Relations URL | https://www.penumbrainc.com/investors/ |
HQ State/Province | California |
Sector | Health Care |
Industry | Health Care Equipment & Supplies |
Equity Style | Small Cap/Growth |
Next Earnings Release | Feb. 21, 2025 (est.) |
Last Earnings Release | Oct. 30, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |
Ratings
Profile
Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are sold to hospitals and are developed for use by specialist physicians. The neurovascular product category contributes to the majority of revenue. Within the neurovascular business, the firm offers products for neurovascular access, ischemic stroke, neurovascular embolization, and neurosurgical tool markets. In the peripheral vascular business, the firm sells devices related to peripheral embolization and peripheral thrombectomy. Penumbra generates the majority of its revenue in the United States. |
URL | https://www.penumbrainc.com |
Investor Relations URL | https://www.penumbrainc.com/investors/ |
HQ State/Province | California |
Sector | Health Care |
Industry | Health Care Equipment & Supplies |
Equity Style | Small Cap/Growth |
Next Earnings Release | Feb. 21, 2025 (est.) |
Last Earnings Release | Oct. 30, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |